The stock has demonstrated consistent upward movement, gaining for five consecutive days and delivering a cumulative return of 4.26% during this period. Trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, Laurus Labs exhibits robust technical strength relative to its historical price trends.
In comparison to the broader market, Laurus Labs outperformed its sector by 1.01% on the day it hit this new high. While the Sensex opened positively with a gain of 91.42 points, it later retreated by 393.30 points, trading at 84,649.07, which is 0.36% lower. Despite this, the Sensex remains close to its own 52-week high of 85,290.06, trading just 0.76% below that level and maintaining a bullish stance above its 50-day and 200-day moving averages.
Over the past year, Laurus Labs has delivered a remarkable return of 112.18%, significantly outpacing the Sensex’s 9.46% performance. The stock’s 52-week low was recorded at Rs.475.45, highlighting the extent of its price appreciation over the period.
Momentum just kicked in! This mid-cap from the Pharmaceuticals & Biotechnology sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- Fresh momentum detected
- Explosive short-term signals
- Early wave positioning
Financially, Laurus Labs has shown strong metrics that underpin its market performance. The company reported a net profit growth of 993.4% in its September 2025 quarter, marking the fourth consecutive quarter of positive results. Profit before tax (PBT) excluding other income stood at Rs.242.77 crores, reflecting a growth of 1233.17%, while profit after tax (PAT) reached Rs.194.97 crores, growing by 882.7%. The operating profit to interest ratio for the quarter was notably high at 10.08 times, indicating efficient management of financial obligations.
Return on capital employed (ROCE) remains strong at 16.75%, signalling effective utilisation of capital resources. Institutional holdings account for 37.63% of the stock, suggesting a significant presence of investors with substantial analytical capabilities and resources.
Despite the impressive short-term gains, the company’s operating profit has grown at an annual rate of 5.37% over the last five years, indicating a more moderate long-term growth trajectory. The stock’s valuation metrics show a ROCE of 14.9 and an enterprise value to capital employed ratio of 8.2, which is considered relatively high. However, the stock trades at a discount compared to its peers’ average historical valuations. Over the past year, while the stock price has risen by 112.18%, profits have increased by 421.7%, resulting in a PEG ratio of 0.2.
Get the full story on Laurus Labs ! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this Pharmaceuticals & Biotechnology mid-cap. Make informed decisions!
- Full research story
- Sector comparison done
- Informed decision support
Market performance over the longer term also favours Laurus Labs, with the stock outperforming the BSE500 index over the last three years, one year, and three months. This consistent outperformance highlights the company’s ability to maintain competitive positioning within the Pharmaceuticals & Biotechnology sector.
In summary, Laurus Labs’ ascent to a new 52-week high of Rs.1033.55 is supported by a combination of strong quarterly financial results, sustained price momentum, and favourable technical indicators. The stock’s performance contrasts with the broader market’s modest retreat, underscoring its relative strength within the sector and market.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
